Navigation Links
Phase 3 Data Show Intravenous Golimumab Inhibited Radiographic Progression in Patients with Active Rheumatoid Arthritis
Date:11/12/2012

itis is a chronic, systemic inflammatory condition that is often characterized by symptoms that include pain, stiffness and inflammation, and in some cases, joint destruction and disability.  It is estimated that 1.5 million Americans[1] and more than 23.5 million people worldwide[2] are affected by the condition, for which there is no cure.

About SIMPONI
SIMPONI is a human monoclonal antibody that targets and neutralizes excess TNF-alpha, a protein that when overproduced in the body due to chronic inflammatory diseases can cause inflammation and damage to bones, cartilage and tissue.  SIMPONI is approved in 57 countries for adult rheumatologic indications, including the United States where SIMPONI received FDA approval in April 2009 for the treatment of moderately to severely active rheumatoid arthritis (RA) with the medicine methotrexate, active psoriatic arthritis alone or with the medicine methotrexate and active ankylosing spondylitis.  SIMPONI is available either through the SmartJect® autoinjector or a prefilled syringe as a subcutaneously administered injection.  For more information about SIMPONI, visit www.SIMPONI.com.  

Applications requesting approval of SIMPONI as a subcutaneously administered anti-TNF-alpha therapy for the treatment of adult patients with moderately to severely active ulcerative colitis have been submitted in Europe and the U.S.

In addition, applications requesting approval of I.V. golimumab for the treatment of adults with moderately to severely active RA have been submitted in the U.S. and Europe.

Janssen Biotech, Inc. discovered and developed SIMPONI and markets t
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 Regado Biosciences, Inc. ... on the Phase 3 clinical development of Revolixys™ Kit ... drug system, today announced that it will hold a ... 12, 2014, at 8:30 a.m. EDT to discuss its ... Interested participants and investors may access the conference ...
(Date:7/29/2014)... 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ... healthcare conferences during the third quarter, the 2014 Avondale ... Healthcare 2014 Conference.  Alexza,s corporate presentation will be webcast ... each event are below: , 2014 Avondale ... Boston , MA.  The format is ...
(Date:7/29/2014)... July 29, 2014  Landauer, Inc. (NYSE: ... radiation measurement and monitoring, outsourced medical physics services and ... for the fiscal third quarter 2014 after the market ... The Company will host a conference call for investors ... Time (10 a.m. Eastern Time). Investors may access the ...
Breaking Medicine Technology:Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2
... , MIAMI , July 21 Understanding ... patient resources. That,s why Puerto Rican actress, author and mother ... partnered with the Asthma and Allergy Foundation of America (AAFA) ... new Spanish asthma education web resource to help patients learn ...
... Trinity Orthopedics LLC, a medical device company that develops and markets ... a Notice of Allowance from the U.S. Patent and Trademark Office for ... posterior fixation system in the United States under the ReStor ... "Recent clinical studies ...
Cached Medicine Technology:Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 2Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 3Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 4Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 5Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 6Trinity Orthopedics Receives Patent Allowance for Sagittally Stable Spinal Fixation System 2
(Date:7/29/2014)... July 29, 2014 New high priced ... Part D by a projected $2.9 to $5.8 billion ... actuarial firm Milliman released today by the Pharmaceutical Care ... premiums could increase by as much as 8.6 percent ... drugs, including Sovaldi and Olysio. , The study finds ...
(Date:7/29/2014)... By Dennis Thompson ... -- Exercise, a healthy diet and good sleep can protect ... down the aging process at a cellular level, researchers report. ... stressful events are linked to increased shortening of telomeres, the ... quickly cells age. "We found that over a one-year ...
(Date:7/29/2014)... 2014 During his 37 years in dental ... Associates, has had a steady stream of college students shadow ... have now gone on to dental school and some are ... shadowing program helps college students find success. , For students ... them the chance to see a realistic view of what ...
(Date:7/29/2014)... Medicine researchers have made an important advancement toward ... deadly tick-transmitted disease, human granulocytic anaplasmosis (HGA). , ... a steady rise in the incidence of human ... the need for a vaccine critical. Successful vaccine ... prevent disease, and the VCU team has identified ...
(Date:7/29/2014)... Boise, Idaho (PRWEB) July 29, 2014 ... & Hart LLP ’s Boise office, has been appointed ... Cross of Greater Idaho. , Busacker is an experienced ... executive compensation matters. He advises clients on a wide ... plan design, plan administration, compliance, and governance concerns. His ...
Breaking Medicine News(10 mins):Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:Healthy Habits May Slow Cellular Signs of Aging, Study Finds 2Health News:Healthy Habits May Slow Cellular Signs of Aging, Study Finds 3Health News:Arthur Bruce Dental Helps College Students 2Health News:Researchers take steps toward development of a vaccine against tick-transmitted disease 2Health News:Researchers take steps toward development of a vaccine against tick-transmitted disease 3Health News:Holland & Hart Partner Brett Busacker Appointed to Board of Directors for American Red Cross of Greater Idaho 2
... (cell culture) research currently underway at the Peninsula Medical School ... and develop therapies for the treatment of multiple tumours in ... a protein called merlin, which in turn cause cancers in ... brain. Schwann cells produce the sheaths that surround and insulate ...
... Makes First Investment in Antibacterial Therapeutics From ... its Biodefense and Pandemic ... today,announced the close of a $30 million Series B financing ... now completing Phase I testing. The financing was led by ...
... Group Calls for Funding Suspension After Trial ... a Baltimore Sun,opinion piece today ( http://www.baltimoresun.com/news/opinion/oped/bal ... suspension of costly HIV vaccine research funding ... proven HIV/AIDS prevention,testing and treatment strategies., ...
... take their lives in the spring, doctors say , , SUNDAY, March ... time of renewal and hope, the greatest number of suicides in ... the American College of Emergency Physicians. , It,s not clear why ... L. Lawrence. But "we do know that suicide is the 11th ...
... Music therapy can help reduce anxiety and improve physical ... everyone has used music at one time or another ... discipline of music therapy takes the use of music ... "Music therapy is an evidence-based practice that can affect ...
... YORK, March 21 Americans with ... their Medicare Advantage Plan have an ... to this report from UnitedHealthcare at:, ... access video, audio, text, graphics and,photos ...
Cached Medicine News:Health News:Research to lead to brain tumor therapies 2Health News:Research to lead to brain tumor therapies 3Health News:Trius Raises $30 Million in Series B Financing 2Health News:HIV Vaccine Funding: 'Enough is Enough,' Says AHF in Baltimore Sun 2Health News:HIV Vaccine Funding: 'Enough is Enough,' Says AHF in Baltimore Sun 3Health News:HIV Vaccine Funding: 'Enough is Enough,' Says AHF in Baltimore Sun 4Health News:Know Suicide's Warning Signs 2Health News:Know Suicide's Warning Signs 3Health News:Music as Medicine 2Health News:Music as Medicine 3
Bi-phasic peristaltic infusion pump for tumescent work....
... a compact system featuring,easy setup and flow ... allowing the use of less,expensive disposable tubing ... office or hospital use, the,PSI-TEC III Infiltrator ... - 5" (w) X 8" (l) X ...
... represents a major advance in the ... procedures. Combined with precision fluid management, ... solid grooved probe design and patented ... been designed to minimize trauma to ...
Inquire...
Medicine Products: